As China’s biopharma sector continues to flourish, the Asia-Pacific (APAC) region is experiencing a substantial transformation in biopharma innovation, outsourcing, and manufacturing. Ian Haydock, Editor-In-Chief, Insights, Asia-Pacific at Citeline, will unpack the far-reaching effects of China’s burgeoning influence during his keynote address at CPHI Japan 2023, scheduled for April 19-21.
Recent setbacks in the US have prompted China to shift its focus toward Southeast Asia and Japan, as these markets present fewer challenges related to representative patient data. Consequently, China’s share of global R&D in new drugs and vaccines has risen to 24%, with the US holding 51%. Dominant therapeutic areas include oncology, rare diseases, and neurology.
This evolution in global biopharma innovation is driving the emergence of new distribution channels and regional manufacturing centers. Japan’s innovation landscape remains robust, albeit with modest growth, while drug pricing systems continue to challenge research-based multinationals operating in the country.
A hallmark of the APAC biopharma sector is its diverse array of smaller innovators, fostering a dynamic and varied supply side teeming with numerous supply partners. CPHI Japan 2023 is set to draw 7,000 executives from 95 countries, marking a return to pre-pandemic levels of participation.
Jenny Leung, Regional Manager, Informa Markets, underscores the keen interest from international players in accessing the Japanese market and forging partnerships with regional suppliers, distributors, and manufacturers. The mounting competition for collaborators and supply chain resources has prompted Japanese companies to engage with potential partners earlier in the process.
To commemorate its 20th anniversary, CPHI Japan 2023 will host an array of special events, including an award ceremony that celebrates the pivotal role of companies in shaping Japan’s thriving pharma industry.
